What Are Wall Street Analysts' Target Price for Bio-Techne Stock?

Minneapolis, Minnesota-based Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets. It is valued at a market cap of $10.1 billion.   

This healthcare company has trailed the broader market over the past 52 weeks. Shares of TECH have declined 7.7% over this time frame, while the broader S&P 500 Index ($SPX) has surged 14.4%. However, on a YTD basis, the stock is up 7.3%, outpacing SPX’s 1.4% uptick.